Cellular biomolecules in illuminated tumor tissue

The term "Cellular biomolecules in illuminated tumor tissue" is a descriptive category used in pharmacological contexts to identify the broad range of molecular substrates—including lipids, proteins, and nucleic acids—that are damaged during light-activated cancer treatments (AdisInsight, 2024). This concept is fundamental to Photodynamic Therapy (PDT) and Photoimmunotherapy (PIT), where a photosensitizing agent is selectively accumulated in tumor cells and subsequently activated by a specific wavelength of light (NCI, 2021). Upon illumination, the photosensitizer facilitates the production of reactive oxygen species (ROS), such as singlet oxygen, which induce oxidative stress and chemical degradation of these biomolecules (StatPearls, 2023). In newer modalities like PIT, light activation of an antibody-dye conjugate (e.g., Cetuximab sarotalocan) leads to physical stress and rapid rupture of the cell membrane (Rakuten Medical, 2020). Because this term encompasses a heterogeneous collection of cellular components rather than a single protein, enzyme, or receptor, it is classified as a site of action rather than a specific molecular target (PubChem, 2024).

Other names

Tumor cell componentsPhotodynamic therapy substratesPhoto-oxidizable biomoleculesIlluminated tumor tissue components

Generation of reactive oxygen species (ROS) via Type I and Type II photochemical reactions, leading to oxidative damage of cellular membranes, proteins, and DNA, or physical disruption of the cell membrane, ultimately causing cell death (StatPearls, 2023; Rakuten Medical, 2020).